This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?
by Kinjel Shah
JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.
AZNNegative Net Change JNJNegative Net Change PFEPositive Net Change
pharmaceuticals
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
by Zacks Equity Research
Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.
NVONegative Net Change LLYPositive Net Change ANIPNegative Net Change CMMBPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?
by Sundeep Ganoria
VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics
by Zacks Equity Research
Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change VKTXPositive Net Change
pharmaceuticals
Top Stock Reports for NVIDIA, Roche & Lam Research
by Mark Vickery
NVIDIA, Roche, and Lam Research lead today's top Zacks reports, showcasing standout growth drivers and sector-specific strengths.
RHHBYNegative Net Change EIXPositive Net Change CIENPositive Net Change NVDAPositive Net Change LRCXPositive Net Change KGCPositive Net Change TGPositive Net Change KEQUPositive Net Change
computers industrial-products pharmaceuticals semiconductor tech-stocks
LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins
by Zacks Equity Research
Eli Lilly's oral GLP-1 pill orforglipron delivers strong A1C reductions in two late-stage diabetes studies, reinforcing its 2026 filing plans.
AZNNegative Net Change NVONegative Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
J&J Bets on MedTech Growth With Orthopaedics Unit Spin-Off Plan
by Kinjel Shah
J&J's surprise plan to spin off its Orthopaedics unit as DePuy Synthes is aimed at sharpening MedTech focus and boosting growth margins.
JNJNegative Net Change MDTNegative Net Change SYKNegative Net Change KVUENegative Net Change
medical medical-devices pharmaceuticals
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
by Zacks Equity Research
VTRS acquires Aculys Pharma to boost its CNS portfolio in Japan, gaining rights to pitolisant and Spydia for narcolepsy and seizure management, respectively.
ALNYNegative Net Change ANIPNegative Net Change VTRSPositive Net Change CMMBPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
by Zacks Equity Research
Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.
NVONegative Net Change LLYPositive Net Change OMERNegative Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?
by Sundeep Ganoria
Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
NVS Reports Positive Late-Stage Data on Kidney Disease Drug
by Zacks Equity Research
Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.
NVSNegative Net Change BAYRYPositive Net Change TVTXNegative Net Change TRMLPositive Net Change
biotechnology medical pharmaceuticals
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)
by Zacks Equity Research
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
REGNPositive Net Change SNYPositive Net Change RHHBYNegative Net Change
biotechnology biotechs gene-therapy pharmaceuticals
Pre-Markets in Green on Strong Q3 Bank Earnings
by Zacks Equity Research
Pre-Markets in Green on Strong Q3 Bank Earnings.
BACPositive Net Change MSPositive Net Change ABTPositive Net Change UALPositive Net Change
airlines finance pharmaceuticals
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
by Zacks Equity Research
ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
ALNYNegative Net Change BCRXPositive Net Change CRMDNegative Net Change ATXSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX?
by Ekta Bagri
Black Diamond Therapeutics focuses on silevertinib, a next-gen EGFR inhibitor for NSCLC, after outlicensing its other lead asset to Servier.
AZNNegative Net Change JNJNegative Net Change BDTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
by Sundeep Ganoria
Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.
RHHBYNegative Net Change PFEPositive Net Change NVONegative Net Change
biotechs medical pharmaceuticals
JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit
by Zacks Equity Research
J&J tops Q3 forecasts, lifts 2025 sales outlook and plans to spin off its struggling Orthopaedics business.
JNJNegative Net Change AMGNNegative Net Change TEVANegative Net Change BAYRYPositive Net Change
pharmaceuticals
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
by Zacks Equity Research
Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.
ALNYNegative Net Change ALLONegative Net Change CMMBPositive Net Change TVRDNegative Net Change
biotechnology biotechs medical pharmaceuticals
NFIB Small-Business Optimism Index Drops in September
by Zacks Equity Research
NFIB Small-Business Optimism Index Drops in September.
GSPositive Net Change WFCPositive Net Change JPMPositive Net Change CPositive Net Change JNJNegative Net Change
finance pharmaceuticals
Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?
by Sundeep Ganoria
ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.
JNJNegative Net Change LLYPositive Net Change ABBVNegative Net Change
earnings medical pharmaceuticals
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
by Kinjel Shah
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
AKBAPositive Net Change IRWDPositive Net Change PSTVNegative Net Change CRDLPositive Net Change PYXSPositive Net Change
pharmaceuticals
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
by Ahan Chakraborty
CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.
PFEPositive Net Change AMPHNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers stock slips below its 50-day average as generic pressure, high debt, and trimmed earnings outlook weigh on sentiment
BMYNo Net Change PFEPositive Net Change MRKPositive Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
by Zacks Equity Research
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
BIIBNegative Net Change FOLDPositive Net Change CRMDNegative Net Change DNLIPositive Net Change
biotechnology biotechs medical pharmaceuticals
Top Stock Reports for Apple, Eli Lilly & Visa
by Mark Vickery
Apple's strong Services growth, Eli Lilly's GLP-1 momentum, and Visa's digital expansion headline today's top stock reports.
AAPLPositive Net Change VPositive Net Change ADPNegative Net Change MRKPositive Net Change LLYPositive Net Change TTENegative Net Change
business-services computers pharmaceuticals